CD274 and non-small cell lung carcinoma: Atezolizumab is a PD-L1-targeting monoclonal antibody approved as first-line monotherapy for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression, and as an adjuvant treatment in patients with resected stage II–IIIA NSCLC7,8.